Targeting angiogenesis in cancer: clinical development of bevacizumab
David J Kerr
Correspondence Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
Email david.kerr@clinpharm.ox.ac.uk
Vascular endothelial growth factor (VEFG) stimulates tumor-associated angiogenesis, thereby making it a prime target for the development of anti-VEGF compounds. One such anti-VEGF drug, bevacizumab, has improved survival rates in some cancer trials. The key clinical trial data and reasons for some of the contrasting results seen in different patient studies are discussed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Monoclonal antibody therapy of cancerNature Biotechnology Research (01 Sep 2005)
See all 16 matches for Research